<b>Gapping up <br/>In reaction to strong earnings/guidance:</b><br/>ESIO +30.3%, NBIX +19.2%, TACT +12.2%, WSTL +11.3%, FMSA +11.2%, PEI +9.7%, SBRA +9.2%, CBPO +8.4%, IMDZ +7.7%, LB +7.5%, (October comps of +2% vs lsd decline prior guidance; sees Q3 EPS to be at the high end of its guidance and reiterates FY 17 EPS guidance of $3.00-3.20; expects Q3 sales of $2618 mln vs $2568 mln consensus), KMT +7.3%, QDEL +6.3%, EXEL +6.1%, ANSS +5.5%, WTI +5.4%, CZR +5%, APRN +4.7%, AN +4.6%, CFMS +4.5%, ABC +4.4%, BLDP +4.1%, HOS +4.1%, CKH +3.7%, RWLK +3.6%, MYRG +3.5%, ZAGG +3.5%, SHAK +3.5%, ULTI +3.4%, CMPR +3.3%, HBM +3.2%, GLUU +3.1%, JUNO +3.1%, HIIQ +3.1%, AREX +2.9%, INAP +2.9%, NMIH +2.8%, TNH +2.7%, DLPH +2.7%, BABA +2.6%, CVE +2.6%, DXCM +2.5%, CF +2.5%, SWM +2.4%, SRC +2%, ALL +1.9%, RGLD +1.7%, ARRS +1.6%, AME +1.6%, SRCI +1.5%, ZUMZ +1.4%, (October comps of +6.6% vs +10.2% year ago and +9.3% last month), ADP +1.3%, BOJA +1.2%, EQIX +1.1%, FLT +1.1%, CI +1.1%, DWDP +1.1%, QCOM +0.9%<br/><b>M&A news:</b><br/>OCRX +65% (to be acquired by Mallinckrodt (MNK) for an upfront payment of $1.52/share and a CVR for up to $2.58/share)<br/><b>Other news:</b><br/>XTNT +14.7% (enters into a distribution agreement with curasan, ' adding a premium line of synthetic scaffolds to its biologics portfolio' )<br/>DRNA +10.8% (Dicerna Pharmaceuticals and Boehringer Ingelheim announce a research collaboration and license agreement to discover and develop novel GalXC RNAi therapeutics for the treatment of chronic liver diseases)<br/>TURN +8% (after reporting NAV per share of $2.68 as of September 30, 2017; third consecutive quarter of NAV growth )<br/>ABY +6.7% (Algonquin to purchase 25% interest in Atlantica Yield from Abengoa at price of $24.25 per share, $2,430 million implied total equity value)<br/>HTGM +4.9% (enters into second statement of work with QIAGEN)<br/>RWLK +3.6% (announces that Germany's national social accident agrees to provide personal exoskeletons to qualifying beneficiaries)<br/>CGEN +3.4% (enters research collaboration with Mount Sinai on novel Myeloid Immuno-Oncology target)<br/><b>Analyst comments:</b><br/>AMED +6.6% (upgraded to Buy from Neutral at Mizuho)<br/>HLS +3.7% (upgraded to Buy from Neutral at Mizuho)<br/>TRHC +2.1% (initiated with an Overweight at First Analysis Sec)<br/>TPR +1.4% (initiated with a Positive at Susquehanna)<br/>EQIX +1.1% (upgraded to Overweight from Neutral at JP Morgan)<br/>DPZ +1% (upgraded to Buy at Maxim Group)<br/>DVN +0.8% (upgraded to Overweight from Equal-Weight at Stephens)<br/><b>Gapping down<br/>In reaction to disappointing earnings/guidance:</b><br/>PI -29.1%, OCLR -18.7%, TCAP -18%, CYH -15.6%, W -13.3%, OSUR -12.5%, TEVA -12.5%, HABT -10.9%, NWL -10.7%, ATRC -10.5%, CIE -10%, THS -9.6%, KEM -9.1%, FEYE -8.7%, GPRO -8.7%, SYMC -7.3%, EPZM -7.1%, CAKE -6.7%, MLM -5.7%, TSLA -5.3%, GNK -5%, HBI -5%, PES -5%, ALIM -4.8%, CLVS -4.6%, GOLD -4.4%, DYN -4.3%, QUOT -3.9%, QRVO -3.8%, INSY -3.7%, PBH -3.7%, FIT -3.5%, WPZ -3.3%, BT -3.2%, CAVM -3.1%, AVP -3%, SAGE -3%, BIOS -2.9%, FATE -2.8%, ADAP -2.8%, BBRG -2.5%, CNAT -2.4%, CHK -2.3%, CTRP -2.2%, GPRE -1.9%, GERN -1.8%, HIVE -1.7%, WPX -1.7%, KHC -1.5%, NUS -1.4%, EPD -1.3%, TICC -1.3%, YELP -1.2%, FB -1.2%, NICE -1.1%, TDOC -1%, XPO -1%, TWI -1%, ERII -0.9%, GCP -0.9%, PAH -0.9%, SNY -0.9%<br/><b>Select Optical related names showing weakness:</b><br/>FNSR -3.1%, ACIA -2.9%, CIEN -1.8%, AAOI -1.2%, FN -1%<br/><b>Other news:</b><br/>NTLA -8.9% (prices underwritten public offering of 6.25 mln shares of its common stock at a public offering price of $24.00 per share)<br/>ASMB -4.7% (prices $2.21 mln shares of common stock at $27.25 per share)<br/>AQN -0.9% (Algonquin to purchase 25% interest in Atlantica Yield from Abengoa at price of $24.25 per share, $2,430 million implied total equity value; AQN to sell on a bought deal basis, 37.8 mln common shares at a price of CAD$13.25/share)<br/><b>Analyst comments:</b><br/>SQ -1.7% (downgraded to Hold from Buy at Stifel)<br/>CRTO -1.3% (downgraded to Hold from Buy at Jefferies)<br/>ZBH -0.5% (downgraded to Neutral from Overweight at Piper Jaffray)<br/><br/>Briefing.com